An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new targets to watch, a growing role for nucleic acid based therapies, and a continued expansion of cell type subsets beyond the commonly used B cells and Tregs.
This year’s meeting, which takes place December 3-6 in San Diego, has a heavy emphasis on hematological malignancies, which account for more than 75% of the preclinical abstracts.
Indeed, BioCentury identified eight new therapeutic targets which all fall in oncology, two of which are new chimeric antigen receptor (CAR) T cell targets in the continually growing cancer immunology space (see “Novel targets at ASH”).
Select new targets for hematological malignancies and other cancers presented at the 2016 American Society of Hematology (ASH) conference. Source: ASH Abstracts
|Target||Standard Indication||Research summary||Institution(s)||Abstract|
|Ankyrin repeat and sterile α motif domain containing 1B (ANKS1B)||Acute lymphoblastic leukemia (ALL)||ANKS1B was confirmed as a target upregulated by the transcription factor 3 (TCF3; E2A)-PBX homeobox 1 (PBX1) fusion found in a subset of B cell ALL patients.||Tampere University Hospital; University of California San Francisco; University of Eastern Finland; University of Helsinki; University of Tampere||4077|
|B-cell receptor-associated protein 31 (BCAP31; BAP31)||Leukemia||BCAP31 was discovered as an additional target of the protein disulfide isomerase (PDI) inhibitor PS89, and its engagement is|